-
Medtronic’s BrainSense Adaptive DBS Wins FDA Approval for Parkinson’s Treatment
•
US-Irish medical device giant Medtronic (NYSE: MDT) announced that the US Food and Drug Administration (FDA) has approved its BrainSense Adaptive deep brain stimulation (aDBS) system and BrainSense Electrode Identifier (EI) for treating Parkinson’s disease (PD). The approval marks a milestone in personalized neurological therapies. Technology HighlightsThe BrainSense system uses…
-
Medtronic Q3 Earnings Show 4.1% Organic Growth, Driven by Cardiac Ablation
•
US-Irish medical device company Medtronic (NYSE: MDT) reported financial results for the third quarter (Q3) of fiscal year 2025 (FY25), which ended on January 24, 2025. The company posted revenues of USD 8.3 billion, marking a 4.1% increase on an organic basis. Segment Performance OutlookMedtronic reiterated its organic revenue growth…
-
Medtronic Secures Exclusive Distribution Rights for Contego’s Neuroguard and Excipio
•
US-Irish firm Medtronic (NYSE: MDT) has entered into an exclusive distribution agreement with Contego Medical, becoming the sole US distributor for Contego’s portfolio of commercially available products. This includes the recently FDA-approved Neuroguard IEP System, a unique 3-in-1 carotid stenting system, and the Excipio Peripheral Thrombectomy Devices. These products are…
-
Medtronic’s BrainSense Technologies Win EU, UK CE Mark for Parkinson’s Treatment
•
US-Irish firm Medtronic (NYSE: MDT) has announced that it has received CE (Conformité Européenne) Mark approval in the European Union (EU) and the United Kingdom (UK) for its BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI). This approval marks a significant breakthrough in the treatment of Parkinson’s…
-
Medtronic’s Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment
•
US-Irish firm Medtronic (NYSE: MDT) has announced that its Harmony Transcatheter Pulmonary Valve (TPV) System has received CE marking, a significant step in expanding its market reach for this minimally invasive alternative to open-heart surgery. The Harmony TPV System is designed for patients with congenital heart disease, specifically those with…
-
Medtronic Reports 5% Organic Revenue Growth in Q2 FY25 with Strong Portfolio Performance
•
US-Irish medical device company Medtronic (NYSE: MDT) has announced its financial results for the second quarter (Q2) of fiscal year 2025, which concluded on October 25, 2024. The company reported a total revenue of USD 8.403 billion for the period, marking a 5.0% increase on an organic basis. Cardiovascular Portfolio…
-
Medtronic Partners with China Resources Guangdong Pharmaceutical at CIIE for Medical Equipment Development
•
US-Irish firm Medtronic (NYSE: MDT) has entered into a partnership with China-based China Resources Guangdong Pharmaceutical Co., Ltd. (HKG: 3320) at the 7th China International Import Expo (CIIE). The collaboration is aimed at developing minimally invasive surgical medical equipment to enhance patients’ diagnosis and treatment experience. Focus on GBA Policy…
-
Medtronic Secures China Market Approval for Pulsed Electric Field Atrial Fibrillation Treatment Devices
•
Medtronic (NYSE: MDT), the US-Irish medical technology giant, has announced that it has received approvals from Chinese regulatory authorities for its innovative heart pulse electric field ablation device and disposable heart pulse electric field ablation catheter. These products, when used in tandem, employ the non-thermal effects of pulsed electric fields…
-
National Healthcare Security Administration Reports Pricing Revisions on Aortic Stent Grafts by Major Manufacturers
•
The National Healthcare Security Administration (NHSA) has reported that 12 device manufacturers, both domestic and international, have revised the pricing of their thoracic aortic stent graft products. Among these companies are the US-Irish firm Medtronic (NYSE: MDT), Shanghai-based MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), W. L. Gore & Associates,…
-
Medtronic Launches Advanced Signia Stapler in China, Expanding Surgical Capabilities
•
Medtronic (NYSE: MDT), the US-Irish medical device giant, has announced the launch of its intelligent surgical stapler, the Signia Stapler, in China. This new device is set to enhance surgical procedures with its advanced features. Originally designed for open surgery, the stapler’s application scenarios have expanded to include laparoscopic surgery,…
-
Medtronic’s Advanced Mazor X Spinal Surgery Robot Receives Chinese Market Clearance
•
Medtronic (NYSE: MDT), the US-Irish medical technology giant, has announced that it has received approval from Chinese authorities for its fully upgraded Mazor X spinal surgery robot integrated platform. This marks a significant milestone for the company’s advanced surgical solutions in the Chinese market. Initially launched in China in 2021,…
-
Medtronic’s RDN System Symplicity Spyral Earns First-Ever NMPA Approval
•
Medtronic (NYSE: MDT), the US-Irish medical device giant, has announced that its Symplicity Spyral renal denervation (RDN) system has become the first of its kind to receive market approval from China’s National Medical Products Administration (NMPA). The company celebrates this milestone, which positions it at the forefront of the RDN…
-
Medtronic’s Kanghui Partners with Huashan Hospital to Create Neuroscience Innovation Platform
•
US major Medtronic, Inc.’s (NYSE: MDT) unit, Kanghui, has entered into a partnership with Huashan Hospital, affiliated with Fudan University in Shanghai, to establish the “Neuroscience Industry Research Medicine Integration Innovation Platform.” This collaboration aims to advance the field of neuroscience, particularly in the areas of cerebrovascular diseases, brain occupying…
-
Medtronic Partners with APMG to Advance Orthopedic Treatment Services in China
•
US-based Medtronic Inc., (NYSE: MDT) has entered into a partnership with China’s private healthcare group Asia Pacific Medical Group (APMG) with the aim of enhancing the implementation and promotion of advanced orthopedic and extrasomatic diagnosis and treatment services in China. Launch of AiBLE Digital Intelligence Orthopedics Integrated SolutionIn a significant…
-
Medtronic Launches AiBLE Orthopedic Ecosystem and Partners with Allinmd Orthopedics in China
•
US-based Medtronic Inc., (NYSE: MDT) has launched AiBLE, an innovative ecological ecosystem concept for orthopedics, in the Chinese market. This collaborative platform aims to connect industry, academia, research, and medicine, leveraging existing orthopedic integration platforms, industry chain capabilities, digitalization, and artificial intelligence technologies. With an open and collaborative approach, Medtronic…
-
Medtronic Partners with Shanghai JiaHui Hospital at CIIE
•
US-based Medtronic Inc. (NYSE: MDT) has announced a partnership with Shanghai JiaHui International Hospital, unveiled at the 5th China International Import Expo (CIIE) held this week. The collaboration aims to enhance patient services, upgrade supply chains, and implement clinical solutions, among other initiatives. Financial details of the partnership were not…
